PHARVARIS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.35 USD | -6.26% |
|
-5.17% | -27.45% |
| May. 09 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
| May. 08 | Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 419.3 | 355.2 | 1,324 | 1,007 | - | - |
| Enterprise Value (EV) 1 | 210.2 | 193.3 | 1,324 | 738 | 875.8 | 593.2 |
| P/E ratio | -9.04 x | -4.63 x | -9.66 x | -7.79 x | -7.45 x | -7.41 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 97.5 x |
| EV / Revenue | - | - | - | - | - | 57.4 x |
| EV / EBITDA | -4.58 x | -2.57 x | -15.4 x | -6.12 x | -6.03 x | -3.76 x |
| EV / FCF | -4.7 x | -2.87 x | - | -5.12 x | -4.61 x | -2.85 x |
| FCF Yield | -21.3% | -34.8% | - | -19.5% | -21.7% | -35.1% |
| Price to Book | 2.05 x | 2.38 x | - | 3.9 x | 9.55 x | 3.24 x |
| Nbr of stocks (in thousands) | 33,129 | 33,788 | 52,109 | 53,817 | - | - |
| Reference price 2 | 12.66 | 10.51 | 25.41 | 18.72 | 18.72 | 18.72 |
| Announcement Date | 3/29/22 | 4/5/23 | 4/10/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 10.33 |
| EBITDA 1 | - | -23.41 | -45.86 | -75.21 | -85.99 | -120.7 | -145.3 | -157.6 |
| EBIT 1 | - | -25.01 | -54.14 | -86.71 | -96.91 | -123.9 | -147 | -161.8 |
| Operating Margin | - | - | - | - | - | - | - | -1,566.73% |
| Earnings before Tax (EBT) 1 | - | -26.07 | - | -75.65 | -99.83 | -119.7 | -148.5 | -163.7 |
| Net income 1 | -8.027 | -26 | -42.73 | -76.33 | -100.9 | -122.1 | -138.8 | -163.7 |
| Net margin | - | - | - | - | - | - | - | -1,585.45% |
| EPS 2 | -1.660 | -5.360 | -1.400 | -2.270 | -2.630 | -2.404 | -2.512 | -2.525 |
| Free Cash Flow 1 | - | -21.54 | -44.73 | -67.29 | - | -144 | -190 | -208 |
| FCF margin | - | - | - | - | - | - | - | -2,014.15% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/20 | 4/29/21 | 3/29/22 | 4/5/23 | 4/10/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | -18.2 | - | - | - | - | - | -24.64 | - | - | - | - |
| EBIT 1 | -16.24 | -19.38 | -21.38 | -22.39 | -23.57 | -21.08 | -22.46 | -26.2 | -27.18 | -28.31 | -30.35 | -32.24 | -34.12 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -9.88 | -10.89 | -38.89 | - | -21.8 | -23.45 | -32 | -27.73 | -31.17 | -33.96 | -36.75 |
| Net income 1 | -12.34 | -16.03 | -12.62 | -8.5 | -39.2 | -22.63 | -21.9 | -23.6 | -32.75 | -28.02 | -29.93 | -31.29 | -32.64 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.0900 | -0.4800 | -0.3800 | -0.2500 | -1.160 | -0.6700 | -0.6300 | -0.5800 | -0.7600 | -0.5200 | -0.5583 | -0.5773 | -0.5993 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/29/22 | 5/11/22 | 9/12/22 | 12/8/22 | 4/5/23 | 5/8/23 | 8/7/23 | 11/2/23 | 4/10/24 | 5/8/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 98.6 | 209 | 162 | - | 269 | 132 | 414 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -21.5 | -44.7 | -67.3 | - | -144 | -190 | -208 |
| ROE (net income / shareholders' equity) | - | -45.4% | -28.4% | -43.1% | - | -45.2% | -83.9% | -59.8% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 19.80 | 6.180 | 4.410 | - | 4.800 | 1.960 | 5.780 |
| Cash Flow per Share 2 | - | -4.430 | -1.470 | -2.000 | - | -2.190 | -2.210 | - |
| Capex 1 | - | - | 0.13 | 0.12 | - | 4.58 | 9.16 | 18.3 |
| Capex / Sales | - | - | - | - | - | - | - | 177.38% |
| Announcement Date | 11/12/20 | 4/29/21 | 3/29/22 | 4/5/23 | 4/10/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
18.72
EUR
Average target price
30.87
EUR
Spread / Average Target
+64.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.45% | 1.1B | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- PHVS Stock
- Financials Pharvaris N.V.
